Skip to main
LSTA

LSTA Stock Forecast & Price Target

LSTA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lisata Therapeutics Inc has shown promising progress in its clinical trials for certepetide, particularly highlighted by the positive preliminary data from Cohort A, which indicated an upward trend in overall survival and recorded four complete responses. The advancements in Cohort B suggest that a second dose of certepetide may enhance both progression-free survival (PFS) and overall response rate (ORR) for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). These key clinical findings reinforce the company's dedication to developing effective therapies for solid tumors, potentially enhancing its value in the competitive pharmaceutical market.

Bears say

Lisata Therapeutics Inc. faces significant risks regarding its future performance primarily due to the uncertainty associated with its clinical trials, where failed or inconclusive results could severely hinder its progress. Additionally, the company may struggle to secure adequate funding necessary to advance its investigational drug, certepetide, through crucial stages of development. These challenges contribute to a negative outlook for the stock, as successful commercialization of its therapies is contingent upon overcoming these substantial hurdles.

LSTA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lisata Therapeutics Inc (LSTA) Forecast

Analysts have given LSTA a Strong Buy based on their latest research and market trends.

According to 2 analysts, LSTA has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lisata Therapeutics Inc (LSTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.